22:06 , Apr 28, 2017 |  BioCentury  |  Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
19:49 , Feb 17, 2017 |  BC Week In Review  |  Company News

Gilead, Amygdala deal

Amygdala acquired GS-6637 from Gilead. Gilead received an equity stake and is eligible for undisclosed milestones and royalties. Amygdala expects to begin two or three Phase II trials this year of GS-6637 in alcohol and...
21:05 , Feb 16, 2017 |  BC Extra  |  Company News

Amygdala acquires addiction candidate from Gilead

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637...